332013-42-0

Basic information

• Product Name: 2-METHYLCARBAMOYLISONICOTINIC ACID ETHYL ESTER
• Synonyms: ETHYL 2-[(METHYLAMINO)CARBONYL]ISONICOTINATE;2-METHYLCARBAMOYLISONICOTINIC ACID ETHYL ESTER;2-[(METHYLAMINO)CARBONYL]-PYRIDINE-4-CARBOXYLIC ACID ETHYL ESTER;2-[(Methylamino)carbonyl]-pyridine-4-carboxylic acid ethylester;4-Pyridinecarboxylic acid, 2-[(methylamino)carbonyl]-, ethyl ester
• CAS NO: 332013-42-0
• Molecular Formula: C₁₀H₁₂N₂O₃
• Molecular Weight: 208.21
• Mol File: 332013-42-0.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 371.4 °C at 760 mmHg
• Flash Point: 178.4 °C
• Appearance: /
• Density: 1.173 g/cm³
• Vapor Pressure: 1.03E-05mmHg at 25°C
• Refractive Index: 1.525
• CAS DataBase Reference: 2-METHYLCARBAMOYLISONICOTINIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 2-METHYLCARBAMOYLISONICOTINIC ACID ETHYL ESTER(332013-42-0)
• EPA Substance Registry System: 2-METHYLCARBAMOYLISONICOTINIC ACID ETHYL ESTER(332013-42-0)

Safety Data

• Hazardous Substances Data: 332013-42-0(Hazardous Substances Data)

Usage

General Description

2-Methylcarbamoylisonicotinic acid ethyl ester is a chemical compound with the molecular formula C11H14N2O4. It is an ester derived from 2-methylcarbamoylisonicotinic acid and ethyl alcohol. 2-METHYLCARBAMOYLISONICOTINIC ACID ETHYL ESTER is a derivative of nicotinic acid, which is a type of B vitamin that plays a role in energy production and metabolism. The ethyl ester form of 2-methylcarbamoylisonicotinic acid is often used in research and pharmaceutical applications, particularly in the development of new drugs and treatments for various medical conditions. Its properties and potential uses make it a subject of interest in the fields of chemistry and pharmacology.

InChI:InChI=1/C10H12N2O3/c1-3-15-10(14)7-4-5-12-8(6-7)9(13)11-2/h4-6H,3H2,1-2H3,(H,11,13)

Upstream product

• 123-39-7 N-Methylformamide 
• 1570-45-2 isonicotinic acid ethylester 

Downstream Products

• 332013-24-8 4-[({4-[(4-chlorophenyl)amino]furo[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methyl-2-pyridinecarboxamide 4-methylbenzenesulfonate 
• 332012-46-1 4-[({4-[(4-methoxyphenyl)amino]furo[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methyl-2-pyridinecarboxamide 
• 332012-57-4 4-[({4-[(3-chlorophenyl)amino]-furo[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methyl-2-pyridinecarboxamide 
• 332013-26-0 4-[({4-[(4-chlorophenyl)amino]furan[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methyl-2-pyridinecarboxamide methanesulfonate 
• 332012-40-5 Telatinib 
• 1547120-68-2 C₂₄H₂₁Cl₂N₅O₂ 
• 1547120-64-8 C₂₃H₁₈Cl₃N₅O₂ 
• 1547120-63-7 C₂₃H₁₈Cl₂FN₅O₂ 
• 1547120-60-4 C₂₃H₁₉Cl₂N₅O₂ 
• 1547120-57-9 C₂₄H₁₉ClF₃N₅O₂ 
• 1547120-56-8 C₂₄H₁₈BrClF₃N₅O₂ 
• 1547120-51-3 C₂₄H₁₈Cl₂F₃N₅O₂ 
• 1547120-50-2 C₂₄H₁₈ClF₄N₅O₂ 
• 1547120-89-7 C₂₄H₁₉ClF₃N₅O₂ 

Relevant articles and documents

Design, synthesis and biological evaluation of indole derivatives as novel inhibitors targeting B-Raf kinase

A series of novel indole derivatives were designed and synthesized and their inhibitory activity against B-Raf and HepG2 cell were also described. Among them, compounds 7a and 7b exhibited excellent potency, which showed the potential for further research

COMPOUNDS FOR TREATING PULMONARY HYPERTENSION

The present invention relates to pharmaceutical compositions and combinations for treating, preventing or managing pulmonary hypertension comprising small molecule heterocyclic pharmaceuticals, and more particularly, substituted pyridines and pyridazines optionally combined with at least one additional therapeutic agent.